CRISPR/Cas9, a powerful tool to target human herpesviruses.
van Diemen FR, Lebbink RJ.
Cell Microbiol. 2017 Feb;19(2). doi: 10.1111/cmi.12694. Epub 2016 Dec 23.
40 Years after the Registration of Acyclovir: Do We Need New Anti-Herpetic Drugs?
Majewska A, Mlynarczyk-Bonikowska B.
Int J Mol Sci. 2022 Mar 22;23(7):3431. doi: 10.3390/ijms23073431.
The trimeric artesunate derivative TF27 exerts strong anti-cytomegaloviral efficacy: Focus on prophylactic efficacy and oral treatment of immunocompetent mice.
Wild M, Bertzbach LD, Tannig P, Wangen C, Müller R, Herrmann L, Fröhlich T, Tsogoeva SB, Kaufer BB, Marschall M, Hahn F.
Antiviral Res. 2020 Jun;178:104788. doi: 10.1016/j.antiviral.2020.104788. Epub 2020 Apr 3.
Variability in the Evaluation and Treatment of Healthy Neonates With Uncomplicated Conjunctivitis.
Nelson C, Deshler BJ, Bernstein B, Aronoff S.
J Pediatr Ophthalmol Strabismus. 2025 Mar-Apr;62(2):143-149. doi: 10.3928/01913913-20241121-04. Epub 2024 Dec 30.
DNA Encapsidation and Capsid Assembly Are Underexploited Antiviral Targets for the Treatment of Herpesviruses.
Keil T, Liu D, Lloyd M, Coombs W, Moffat J, Visalli R.
Front Microbiol. 2020 Aug 12;11:1862. doi: 10.3389/fmicb.2020.01862. eCollection 2020.
In vivo proof-of-concept for two experimental antiviral drugs, both directed to cellular targets, using a murine cytomegalovirus model.
Sonntag E, Hahn F, Bertzbach LD, Seyler L, Wangen C, Müller R, Tannig P, Grau B, Baumann M, Zent E, Zischinsky G, Eickhoff J, Kaufer BB, Bäuerle T, Tsogoeva SB, Marschall M.
Antiviral Res. 2019 Jan;161:63-69. doi: 10.1016/j.antiviral.2018.11.008. Epub 2018 Nov 17.
Prevention and control of herpesvirus diseases. Part 1. Clinical and laboratory diagnosis and chemotherapy. A WHO meeting.
A WHO Meeting.
Bull World Health Organ. 1985;63(2):185-201 contd.
